Sareum Holdings (GB:SAR) has released an update.
Sareum Holdings PLC successfully raised £2.364 million to fund the development of its lead drug candidate SDC-1801 for Phase 2 clinical trials, targeting autoimmune diseases like psoriasis. The funds will support longer-term toxicology studies to validate safety and prepare for regulatory submissions, after SDC-1801 showed a favorable safety profile and promising pharmacokinetics in its Phase 1 trial. This capital boost aims to position SDC-1801 as a best-in-class TYK2/JAK1 inhibitor in a market with a significant unmet medical need.
For further insights into GB:SAR stock, check out TipRanks’ Stock Analysis page.
